Clinical Trials in Highlands Ranch, Colorado
42 recruiting
Showing 1–20 of 41 trials
Recruiting
Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,295 enrolled836 locationsNCT05812807
Recruiting
Phase 3
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Renal Cell Carcinoma (RCC)Clear Cell Renal Cell CarcinomaStage II Renal Pelvis Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,040 enrolled410 locationsNCT06661720
Recruiting
Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Anatomic Stage II Breast Cancer AJCC v8Early Stage Breast CarcinomaAnatomic Stage I Breast Cancer AJCC v8
Alliance for Clinical Trials in Oncology1,524 enrolled631 locationsNCT06876714
Recruiting
Phase 3
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled233 locationsNCT07061977
Recruiting
Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled536 locationsNCT06058377
Recruiting
Phase 2Phase 3
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
NRG Oncology1,912 enrolled1056 locationsNCT05174169
Recruiting
Phase 2Phase 3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled494 locationsNCT05987241
Recruiting
Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Stage III Prostate Cancer AJCC v8Prostate AdenocarcinomaStage IVA Prostate Cancer AJCC v8
NRG Oncology1,209 enrolled398 locationsNCT05946213
Recruiting
Phase 3
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225
Recruiting
Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
NRG Oncology3,960 enrolled1238 locationsNCT05879926
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled282 locationsNCT06136624
Recruiting
Phase 2Phase 3
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Renal Pelvis and Ureter Urothelial Carcinoma
National Cancer Institute (NCI)249 enrolled258 locationsNCT04628767
Recruiting
Phase 2
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Metastatic Salivary Gland CarcinomaStage III Major Salivary Gland Cancer AJCC v8Stage IV Major Salivary Gland Cancer AJCC v8+2 more
NRG Oncology146 enrolled150 locationsNCT05408845
Recruiting
Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Locally Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8
NRG Oncology474 enrolled471 locationsNCT05624996
Recruiting
Phase 2
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Metastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8+1 more
NRG Oncology240 enrolled318 locationsNCT05327686
Recruiting
Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
NRG Oncology486 enrolled211 locationsNCT07097142
Recruiting
Phase 1Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Advanced Liver Cancers
Hoffmann-La Roche518 enrolled33 locationsNCT04524871
Recruiting
Phase 3
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Stage I Breast Cancer
NRG Oncology1,670 enrolled832 locationsNCT04852887
Recruiting
Phase 3
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Endometrial Cancer
Karyopharm Therapeutics Inc276 enrolled217 locationsNCT05611931